Compressed sensing decoded pooled testing significantly decreases the number of tests required to identify infected samples. by Kody A. Waldstein (14002708)

Distribution of digital financial inclusion impact on carbon intensity gap in agriculture by province. by Lingzhi Tan (19146572)

Profile of adverse events (AE) based on initial dose of enzalutamide. by Shunsuke Tsuzuki (11512686)

Significant Decrease in Vessel Count of Trade Vessels in (a) Bosporus Strait and (b) Bab el-Mandeb Strait. by Cherryl Chico (20978829)

Adverse events and adverse drug reaction in geriatrics. by Jae Gyoon Kim (16426036)

Subjects:

M^pro confers a significant reduction in growth in yeast caused by decreases in a variety of cellular proteins. by Jin Ou (16914305)

Adverse event severity based on age, gender, dose and time to onset. by Louis Okeibunor Odeigah (13250062)

Subjects:

Adverse event categories based on age, gender, dose, and time to onset. by Louis Okeibunor Odeigah (13250062)

Subjects:

Significant variables in decreasing importance for varietal clustering based on Random forest method. by Wilfried Chevalier (10521466)

Spleen PAX5 significantly decreased in APRIL/BLyS blockade treated mice. by Natalie M. Bath (6316517)

Arctigenin decreased proliferation in colorectal cancer cells with no significant effect on normal cells. by Xiang-Fan Chen (13932983)

Cabozantinib significantly decreases tumor volume and prolongs survival in SCNPC PDX models. by Mark P. Labrecque (10011469)

Estimated prevalence (A), DALYs (B), and mortality (C) rates for IBD among WCBA by 2040. by Jiefeng Zhao (9090305)

Subjects:

Catalytic fold of WT PARG1 C1-GAP domain for RhoA interaction. by Zen Kouchi (14898435)

Spatial heterogeneity in the impact of digital financial inclusion on the carbon reduction gap in agricultural regions. by Lingzhi Tan (19146572)

Table1_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Image3_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.JPEG by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table4_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table2_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”

Table3_Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.XLSX by Xianglin Pan (4441699)

“…Among the factors significantly influencing oxaliplatin-related neurological adverse events, male sex and combination medication decreased the risk of neurological adverse events, while higher cumulative dose increased the risk.…”